Results 61 to 70 of about 787 (175)

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

open access: yesJEADV Clinical Practice, Volume 5, Issue 2, Page 373-384, June 2026.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender   +2 more
wiley   +1 more source

Spesolimab in patients with flare of generalized pustular psoriasis: A multicentre case‐series

open access: yesJournal of the European Academy of Dermatology and Venereology, 2023
Dear Editor,Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening, chronic inf lammatory disease character-ized by acute f lares of pustular eruptions that can be accom-panied by systemic inf lammation.
F. Bellinato   +12 more
openaire   +4 more sources

French guidelines on systemic treatments for moderate‐to‐severe psoriasis in adults: Update 2025

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 6, Page 963-979, June 2026.
New 2025 French guidelines update psoriasis management with revised algorithms integrating recent systemic therapies. They recommend methotrexate, adalimumab or ustekinumab as first‐line treatments and provide guidance for special psoriasis forms, comorbidities, pregnancy and long‐term management.
Marie Masson Regnault   +51 more
wiley   +1 more source

T Cell Immunosenescence in Inflammatory Skin Diseases: Pathogenesis and Therapeutic Targets

open access: yesAging Cell, Volume 25, Issue 5, May 2026.
Immunosenescent T cells promote inflammatory skin diseases such as psoriasis, atopic dermatitis, rosacea, and seborrheic dermatitis via hyperactive signaling networks and SASP secretion. Consequently, intercepting downstream SASP, inhibiting internal pathways, or utilizing senolytics represents promising therapeutic interventions.
Conghui Liu   +3 more
wiley   +1 more source

Spesolimab for the treatment of generalized pustular psoriasis: A real-world analysis of 31 cases

open access: yesPifu-xingbing zhenliaoxue zazhi
Objective To evaluate the efficacy and safety characteristics of spesolimab in real-world clinical practice among patients with generalized pustular psoriasis(GPP).
LIU Runqiu   +5 more
doaj   +1 more source

Juvenile Generalized Pustular Psoriasis: Management in Children—A Case Series

open access: yesClinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Juvenile Generalized Pustular Psoriasis (GPP) is an extremely rare and potentially life‐threatening inflammatory disease. We report three cases of Juvenile GPP that presented with recurrent episodes of widespread painful erythema with sterile pustules accompanied by fever and malaise.
Punam Mishra, Anupa Khadka
wiley   +1 more source

Spesolimab. Anti-IL-36R monoclonal antibody Treatment of generalized pustular psoriasis Treatment of immune-mediated inflammatory diseases

open access: yes, 2023
The palette of biologic therapy is growing rapidly to improve the treatment and management of inflammatory immune-driven diseases. The interleukin-36 (IL-36) receptor has become a prom-ising target for therapeutic intervention, with early studies of anti-
Thomsen, Simon Francis   +7 more
core   +1 more source

Palmoplantare Pustulose: Entstehung, Differentialdiagnose und Therapie

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 4, Page 516-536, April 2026.
Zusammenfassung Die palmoplantare Pustulose (PPP) ist eine chronisch entzündliche, häufig schmerzhafte Erkrankung mit sterilen Pusteln an Handflächen und Fußsohlen, die die Lebensqualität stark einschränkt. Frauen sind häufiger betroffen als Männer, und Rauchen ist ein bedeutender Provokationsfaktor.
Rotraut Mössner   +5 more
wiley   +1 more source

Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa:A randomized double-blind placebo-controlled clinical trial [PDF]

open access: yes
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a considerable disease burden. Existing treatment options are limited and often suboptimal; a high unmet need exists for effective targeted therapies.
Ranganathan, Usha   +10 more
core   +1 more source

Spesolimab for generalized pustular psoriasis: a review of two key clinical trials supporting initial US regulatory approval

open access: yesFrontiers in Immunology
Generalized pustular psoriasis (GPP) is a chronic, rare, and potentially life-threatening inflammatory disease, characterized by the rapid and widespread eruption of small, sterile pustules with surrounding skin erythema.
Eran C. Gwillim   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy